Chemotherapy for Malignant Melanoma: High Doses and Combinations
Author Information
Author(s): S. Lakhani, P. Selby, J.M. Bliss, T.J. Perren, M.E. Gore, T.J. McElwain
Primary Institution: Institute of Cancer Research, Royal Marsden Hospital
Hypothesis
Does high-dose chemotherapy or combination chemotherapy improve response rates in malignant melanoma without extending survival?
Conclusion
High-dose treatments and combination chemotherapy resulted in higher response rates but did not prolong survival in patients with malignant melanoma.
Supporting Evidence
- Response rates for combination and high-dose chemotherapy were higher than those of single-agent vindesine.
- Despite higher response rates, there was no difference in overall survival among treatment regimens.
- Factors associated with longer survival included absence of visceral metastases and good performance status.
Takeaway
Doctors tried stronger and mixed medicines to help people with a serious skin cancer, but it didn't help them live longer, just made them feel better for a while.
Methodology
Retrospective analysis of 164 patients treated with four different chemotherapy regimens between 1976 and 1986.
Potential Biases
The study's design may introduce bias due to non-randomized treatment groups.
Limitations
The study was retrospective and not randomized, which may affect the reliability of the comparisons.
Participant Demographics
Patients had symptomatic and/or visceral metastatic malignant melanoma, with a median age of 45.1 years.
Statistical Information
P-Value
0.001
Confidence Interval
95% CI 2.5, 53.2
Statistical Significance
p<0.005
Want to read the original?
Access the complete publication on the publisher's website